TG Therapeutics, Inc. (TGTX)

NCM – Real vaqt narxi. Valyuta: USD

49.56

-0.34 (-0.68%)

Bozor ochiq: Aug 12, 2026, 2:24 PM EDT

49.90

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

03.08.2026

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

TG Therapeutics, Inc. remains a Buy as BRIUMVI's momentum supports a durable, growing multiple sclerosis franchise. TGTX's Q2 saw BRIUMVI revenue surge 64% YoY to $228 million, prompting 2026 guidance to $950 million, though net income was impacted by manufacturing investments. Subcutaneous BRIUMVI, with Phase 3 data expected late 2026 or early 2027, could expand the addressable market and drive future gross margin tailwinds.

03.08.2026

TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down

TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.

03.08.2026

TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript

03.08.2026

Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings

The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

03.08.2026

TG Therapeutics Q2 Earnings Call Highlights

TG Therapeutics NASDAQ: TGTX reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company cited record new patient starts, continued prescriber expansion and higher-than-expected treatment persistence.

03.08.2026

Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble

Top-notch biotech stocks TG Therapeutics and Twist Bioscience took a tumble Monday on mixed second-quarter reports.

03.08.2026

TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

TG Therapeutics (TGTX) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.17 per share a year ago.

Videolar

No Data

There is no data to display

Press-relizlar

03.08.2026

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950 million and raises full year 2026 BRIUMVI U.S. net product revenue target to approximately $890 - 905 million Conference call to be held today, Monday, August 3, 2026, at 8:30 AM ET NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S.

TG Therapeutics, Inc. (TGTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

TG Therapeutics, Inc. (TGTX)

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down

TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings

TG Therapeutics Q2 Earnings Call Highlights

Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble

TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

Videolar

No Data

Press-relizlar

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down

TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings

TG Therapeutics Q2 Earnings Call Highlights

Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble

TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

Videolar

No Data

Press-relizlar

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

Search stocks

TG Therapeutics, Inc. (TGTX)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

TG Therapeutics, Inc. (TGTX)

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down

TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings

TG Therapeutics Q2 Earnings Call Highlights

Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble

TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

Videolar

No Data

Press-relizlar

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down

TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript

Here's What Key Metrics Tell Us About TG Therapeutics (TGTX) Q2 Earnings

TG Therapeutics Q2 Earnings Call Highlights

Why This Top-Notch Trio Of Biotech Stocks Just Took A Tumble

TG Therapeutics (TGTX) Misses Q2 Earnings Estimates

Videolar

No Data

Press-relizlar

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance